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Abstract
Background: Targeted gene transfection remains a crucial issue to permit the real development
of genetic therapy. As such, in vivo targeted transfection of specific subsets of hematopoietic stem
cells might help to sustain hematopoietic recovery from bone marrow aplasia by providing local
production of growth factors.
Methods: Balb/C mice were injected intravenously, with an anti-mouse c-kit (CD117) monoclonal
antibody chemically coupled to a human IL-3 gene-containing plasmid DNA. Mice were sacrificed
for tissue analyses at various days after injection of the conjugates.
Results: By ELISA, the production of human IL-3 was evidenced in the sera of animals 5 days after
treatment. Cytofluorometric analysis after in vivo transfection of a reporter gene eGFP
demonstrated transfection of CD117+/Sca1+ hematopoietic immature cells. By PCR analysis of
genomic DNA and RNA using primer specific pIL3 sequences, presence and expression of the
human IL-3-transgene were detected in the bone marrow up to 10 days in transfected mice but
not in control animals.
Conclusions: These data clearly indicate that antibody-mediated endocytosis gene transfer allows
the expression of the IL-3 transgene into hematopoietic immature cells, in vivo. While availability of
marketed recombinant growth factors is restricted, this targeting strategy should permit delivery
of therapeutic genes to tissues of interest through systemic delivery. In particular, the ability to
specifically target growth factor expression into repopulating hematopoietic stem cells may create
new opportunities for the treatment of primary or radiation-induced marrow failures.
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Introduction
In vivo gene targeting of highly specific cell subsets
remains the main challenge for gene therapy of a broad
range of conditions associated with acquired diseases,
including infectious disorders, cancer and failure of the
hematopoietic system [1,2]. In vivo gene transfection is
more appealing than in vitro transfection of an aliquot of
cells or tissue that would be then reinfused to the patients,
because it potentially concerns the total population of tar-
geted cells disseminated in the whole body; this is partic-
ularly relevant to patients with primary or secondary
failures of the hematopoietic system, since, in most
instances, residual foci of hematopoiesis exist that cannot
be easily located and cannot be collected by a marrow har-
vest procedure. In vivo targeted transfection of specific
subsets of hematopoietic stem cells (HSC) might help to
sustain hematopoietic recovery from bone marrow apla-
sia by providing local production of growth factors.
Systemic gene delivery systems are needed for therapeutic
applications in which the target cells are not directly acces-
sible [3]. However, for several reasons including lack of
cell specificity and safety, in vivo targeted gene transfer
cannot use current viral vectors. Although cationic lipo-
somes have been promising systems in transfecting cells
in tissue culture, it has been recognised that their in vitro
efficiency does not correlate with their ability to deliver
DNA after in vivo administration [4-10].
Tissue-specific targeting can be achieved through ligand
receptor interactions [11,12]. We have already described a
technique of antibody-mediated targeted gene transfec-
tion termed antibody delivery system [11,12]: a ligand
(capable of binding to the surface of the targeted cells)
conjugated with plasmid DNA retains its ability to specif-
ically interact with cognate receptors on the cell surface.
In previous studies, antibodies directed against internal-
ised cell surface antigens such as the T lymphocyte-related
CD3 molecule or the B lymphocyte-related surface IgD
were chemically coupled to purified plasmid DNA encod-
ing various reporter genes. This approach was validated
both in vitro by the transfer of G418 resistance (neor) into
human T-cell lines [13] or human hematopoietic imma-
ture cells [14] and in vivo by the transfer of β-galactosidase
activity into mouse splenocytes [13]. We have reported
that this strategy can be applied to targeted gene delivery
to human renal carcinoma cells [15]. More recently, in
vivo, we have shown a specific tumor targeting after a sin-
gle intravenous injection in mice bearing tumour express-
ing the renal carcinoma – related G250 tumor associated
antigen [16].
We have previously reported that the method is suitable
for the production of a functional growth factor in specif-
ically CD117+ targeted cells, mediating an in vitro biolog-
ical effect on hematopoiesis [14]. As our previous report
evidenced interaction of the conjugate with hematopoi-
etic cells in vitro, this study was focused on specific in vivo
targeting of hematopoietic tissues.
In the present study, we used anti-CD117 (c-kit) mAb cov-
alently coupled to human IL-3-encoding plasmid DNA.
CD117 antigen is expressed on a CD34+ hematopoietic
subpopulation and is readily internalised upon binding to
its ligand [17]. Thus, targeted-gene transfer through
CD117 may be achieved in this cell subset. We indeed
demonstrated an in vivo targeting of hematopoietic imma-
ture cells via a systemic route, mediating an efficient in
vivo transgene expression.
Methods
Ab-DNA conjugation
The human IL-3 coding sequence (R&D Systems, Minne-
apolis, Minnesota) was ligated to synthetic fragments con-
taining the natural leader sequence of human IL-3 and
was subcloned into pCEP4 vector (Invitrogen Corpora-
tion). Transgene expression was controlled by the cytome-
galovirus (CMV) enhancer-promoter sequence. The
Epstein-Barr Virus replication (oriP) and nuclear antigen
(encoded by the EBNA-1 gene) were carried by this plas-
mid to permit extrachromosomal replication in human,
primate and canine cells [18]. pCEP4 also carries the
hygromycin B resistance gene for stable selection of trans-
fected cells. The resulting vector was named pIL3.
IgG mAbs were chemically coupled to plasmid DNA as
previously described [13]. Briefly, purified IgG (3 mg/ml)
in borate buffer (pH 8.2) (100 mM boric acid, 25 mM
sodium tetraborate, and 75 mM NaCl) were activated
using 3 mg/ml (final concentration) of benzoquinone
(Sigma-Aldrich, St Louis, Missouri, USA). After gel filtra-
tion through a G25 column (Roche Diagnostics, Man-
nheim Germany) activated IgG were then covalently
linked to pIL3 24 hours, in 0.1 M carbonate buffer (pH
8.7), in a ratio of 100 µg of plasmid DNA for 10 µg of IgG
antibody. IgG-plasmid conjugates were then purified by
HPLC. Antibodies used was clone 2B8 a monoclonal rat
anti mouse IgG reacting with the mouse p145 c-kit pro-
tein (CD117) (BD Biosciences Pharmingen Tullastrasse,
Heidelberg, Germany). The negative control was the
mouse G250 IgG1 mAb reacting with human renal cell
carcinoma (kindly provided by Dr A. Gorter, The Nether-
lands) [19]. The quantities of conjugates were expressed as
the quantities of plasmid initially used for reaction.
In vivo transfection assessment
We have previously shown that in vitro transfection of
HSC may be observed in a dose-dependent effect for up to
100 µg of conjugate [14].Genetic Vaccines and Therapy 2004, 2:16 http://www.gvt-journal.com/content/2/1/16
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BalbC mice (6 weeks) were intravenously injected with a
dose of up to 400µg of monoclonal 2B8 (BD Biosciences
Pharmingen) covalently coupled to the pIL3 plasmid
(named conjugate) and as negative control the mono-
clonal 2B8 and plasmid DNA uncoupled (named uncon-
jugate) or irrelevant human monoclonal antibody (G250)
covalently coupled to the pIL3 plasmid (named control
conjugate) or physiological serum (named control
serum).
In a set of experiments, two intraperitoneal injections of
chloroquine (32.5 mg/kg) were performed 2 hours and
just a few minutes before intravenous injection of conju-
gates. The tolerance of chloroquine (used to prevent the
degradation of the plasmid for transfection assays, 20)
was in the range reported in mice for the study of malaria
treatment [21]. Monoclonal antibody (mAb) 2B8 (BD
Biosciences Pharmingen) was covalently coupled to 100
µg of the enhanced green fluorescent protein encoding plas-
mid pEGFP-1 provided from Clontech and was named
eGFP conjugate.
Mice were intravenously injected twice (day 0 and day 2)
and euthanasied 5, 7 or 10 days after the first injection of
the conjugate, after proper anaesthesia.
Human IL-3 production in serum was assayed by High
Sensitivity ELISA (R & D Systems). Controls were sera or
cell culture supernatants of control mice (unconjugate,
control conjugate, control serum).
After euthanasia, the presence of the transgene was inves-
tigated in blood, brain, lungs, liver, spleen, kidneys, adre-
nal glands and bone marrow. In order, to observe toxicity
the weight of mice and their organs were measured (brain,
lungs, liver, spleen, kidneys).
In mice injected with eGFP conjugate, a MACS magnetic
cell separation systems (Miltenyi Biotec, Sunnyvale, CA)
was used to enrich cells expressing CD117 and Sca1 from
mononuclear bone marrow cells. Negative and positive
cells were collected for experimental use. To achieve a
purity greater than 50%, it was necessary to perform two
sequential passes through magnetic columns. The overall
recovery of CD117 was about 30% and enrichment 40
fold, as assessed by the fraction of CD117/Sca1 positive
population before and after separation. Cells were ana-
lysed by flow cytometry to determine the purity of cell
fractions. Then the presence of eGFP positive cells was
investigated by flow cytometry into negative fraction
(CD117/Sca1 negative populations) and positive cell frac-
tions (CD117/Sca1 positive populations). All experi-
ments were conducted according to French regulation for
animal experimentation (Ministry of agriculture Act
No.87848, 1987).
Long-term cultures
Long-term cultures of bone marrow cells were performed,
as previously described [22]. At one week, 50 µg/ml of
hygromycin were added to the long-term culture, in order
to select for stably transfected cells (plasmid conferred
hygromycin resistance to stably transfected cells). After 1-
week selection, these cells were cultured 2 weeks in long-
term culture medium. Viable cells were numbered using
trypan blue exclusion assay.
Clonogenic hematopoietic progenitor assay
5 × 105 cells from bone marrow were assayed for clono-
genic hematopoietic immature cells [23]. Briefly, cells
were plated in triplicate in 35-mm dishes at a concentra-
tion of 5 × 105  cells/ml in complete methylcellulose
M3434 from Stem Cell Technologies (West Broadway,
Vancouver, Canada). Cultures were incubated at 37°C in
5% CO2 and removed at 14 days. Colonies were defined
as containing more than 40 cells using an inverted micro-
scope. Cells were then harvested and studied for IL-3 gene
expression. Two weeks post-transfection, semi-solid colo-
nies were removed from methylcellulose culture for PCR
analysis of the presence of the pIL3 plasmid.
DNA and RNA analyses
The simultaneous isolation of total cellular RNA and DNA
from tissues or cells was performed using TriPure Isola-
tion Reagent Kit (Roche Diagnostics) [24]. Total cellular
RNA was incubated 30 min in the presence of RNAse-free
DNAse (Invitrogen), heated at 90°C for 5 min and
promptly cooled at 4°C. The RT-PCR was then carried out
as previously described [25]. Briefly, total cellular RNA
was first annealed with 1 mM of oligo-dT15 (Sigma-
Aldrich) and then incubated at 42°C for 1 hour in the
presence of 100 units of Moloney murine leukemia virus
reverse transcriptase (Invitrogen) in a final volume of 20
µl. DNA or the reverse transcriptase reaction mixtures
were then subjected to PCR amplification using sense
primer (GTGGTTTGTCCAAACTCATC) and anti-sense
primer (AGAGCTCGTTTAGTGAACCG) located on both
sides of the IL-3 gene (into the multiple cloning site of
pCEP4), which resulted in a PCR product specific of the
gene inserted in the pCEP4. Nested PCR was performed
using sense (CCAAACTCAATGTATCTTATCATGTCT) and
anti-sense (TCAGATTCTAGAAGCTTGGGT) primers
localized in the multiple site of clonage of pCEP4 plas-
mid. These pairs of primers allow for detection of a 542 bp
fragment when electrophoresed on a 2% agarose gel and
visualization with ethidium bromide. Specificity of PCR
products was controlled using an internal 33P-5'-end
labeled oligo-probe specific of human IL3 coding sequence
(ACGGCCGCACCCACGCGACA), in Southern blot anal-
ysis as previously described [26]. To detect a false positive
due to plasmid contamination, we have tested RNA sam-
ples by direct amplification of RNA (without the reverseGenetic Vaccines and Therapy 2004, 2:16 http://www.gvt-journal.com/content/2/1/16
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transcription step). Indeed in the absence of plasmid, Taq
pol will be unable to amplified RNA whereas a PCR prod-
uct would be observed if the RNA sample was contami-
nated with plasmid DNA. No DNA plasmid
contamination was observed for all the assayed RNA sam-
ples. As internal control a 590 bp region of the endog-
enous mouse RAP-SYN gene was also amplified using a
second set of unique 30 bp primers (sense: AGGACT-
GGGTGGCTTCCAACTCCCAGACAC, anti-sense: AGCT-
TCTCATTGCTGCGCGCCAGGTTCAGG), which allows
the detection of a 590 bp fragment [27].
Results
Assessment of transgene product secretion
Balb/C mice were intravenously injected twice (day 0 and
day 3), with the anti-mouse CD117 (c-kit) 2B8 mAb con-
jugated to pIL3 expression vector. Control animals
received unconjugated pIL3 expression vector and 2B8
mAb (named control unconjugate) or irrelevant G250
mouse mAb covalently coupled to the pIL3 plasmid
(named control conjugate) or physiological serum
(named control serum). To increase the transgene
processing into cells, mice were injected with the conju-
gate up to a dose of 400µg in the presence or not of chlo-
roquine known to diminish endosomal DNA degradation
[20]. Mice were euthanasied 5, 7 or 10 days after the first
injection of the conjugate. The presence of human IL-3 in
serum was measured by a human IL3 specific ELISA, from
5 to 10 days. Using 400µg of conjugate in the presence of
chloroquine, we detected human IL-3 in the serum of
mice at 50 pg/ml at day 5 (table 1). No human IL-3 was
observed in the serum of mice sacrificed at days 7 and 10
nor in mice injected with lower dose of conjugate, with
control unconjugate or control conjugate (data not
shown).
Assessment of transfection cell specificity
Gene targeting was then evaluated by injecting mice with
eGFP conjugated or unconjugated to either 2B8 mAb or to
G250 control mAb. At day 5, the presence of transfected
cells into bone marrow mononucleated cells was analysed
into the purified CD117- and CD117+ subpopulations,
by flow cytometry using anti-CD117 and anti-Sca1 Abs.
As shown in Table 2, 4.7% cells from the CD117+/Sca1-
and 2.8% cells from the CD117+/Sca1+ subpopulations
collected from mice injected with the eGFP-2B8 conjugate
were positive. All controls were negative.
Table 1: Detection of circulating human IL-3 in mouse serum at day 5 post injection of pIL3 conjugate
Treatment (IP injection) Quantity of conjugate pg/ml of human IL-3 in mice
Chloroquine unconjugate conjugate
mean sd mean Sd
01 0 0 µg0 0 0 0
04 0 0 µg0 0 0 0
2 × 32.5 mg/kg 100µg0 0 0 0
2 × 32.5 mg/kg 400µg0 0 5 0 * 1 7
The presence of human IL-3 in serum was investigated by ELISA. The data are representative of three independent experiments and are the mean 
of triplicate determinations ± S.D. * indicates statistically significant differences by Student's t-test analysis; p < 0.007 as compared to 400µg of 
unconjugate.
Table 2: Detection of transfected cells in bone marrow mononucleated cells at 5 day postinjection of eGFP conjugate
plasmid eGFP
Cell population Control serum Unconjugate Control conjugate Conjugate
M N C 0000
C D 1 1 7 - 0000
C D 1 1 7 - / S c a 1 - 0000
CD117+/Sca1- 0 0 0 4.7%
CD117+/Sca1+ 0 0 0 2.8%
The presence of transfected cells (eGFP positives) in bone marrow was investigated 5 days postinjection among mononucleated cells (MNC): 
CD117 negative cell population (CD117-), CD117/Sca1 negative cell population (CD117-/Sca1-), CD117 positive/Sca1 negative (CD117+/Sca1-) 
and CD117/Sca1 positive cell population (CD117+/Sca1+). In all cases no transfected cells were observed in the controls.Genetic Vaccines and Therapy 2004, 2:16 http://www.gvt-journal.com/content/2/1/16
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Assessment of transfection tissue specificity
To assess the tissue specificity of the targeting, presence of
pIL3 plasmid was investigated in bone marrow, blood
cells, liver, spleen, lungs, kidneys, adrenal glands, and
brain. PCR analysis of genomic DNA and RNA isolated
from bone marrow and blood (or serum) was performed
using primer specific pIL3 sequences. Specificity of the
PCR and RT-PCR products was assessed by a Southern
blot hybridised with a specific radiolabelled human IL3
probe. The expected 542 bp band of the PCR product cor-
responding to the IL3-transgene presence (both DNA and
RNA) were was specifically detected in the bone marrow
of transfected mice up to 7 days for RNA and 10 days for
DNA, post transfection (figure 1). Nested PCR also was
positive for the IL3 transgene DNA in the spleen of trans-
fected animals up to day 7 (not shown). In control ani-
mals (control serum, unconjugate, control conjugate),
pIL3 DNA but no RNA was detected in peripheral blood
but not in serum until day 5 after the first injection and
then disappeared (figure 2); there was no detection of
DNA or RNA in bone marrow (figure 1). Aside from this,
all other tissues were negative when assayed by nested
PCR on day 5, 7, 10 in transfected animals. IL3 transgene
DNA was only found in the kidney of control animals
receiving an unconjugated mixture of Ab and DNA or the
control conjugate, on day 5 only (not shown).
Nested PCR detection of pIL3 plasmid in bone marrow 5, 7, and 10 days after injection of the conjugate Figure 1
Nested PCR detection of pIL3 plasmid in bone marrow 5, 7, and 10 days after injection of the conjugate. Mice were intrave-
nously injected twice with 100µg of anti-CD117-pIL3 conjugate (at day 0 and at day 2). Control groups corresponded to bone 
marrow of mice treated with unconjugated pIL3 and anti-CD117 Abs or control conjugate (G250-pIL3). IL3 DNA and RNA 
were detected in the bone marrow of animals receiving the pIL3-anti CD117 conjugate up to day 10. The data are representa-
tive of three independent experiments.
Nested PCR detection of pIL3 plasmid in mononuclear peripheral blood cells 5, 7, and 10 days after injection of the conjugate Figure 2
Nested PCR detection of pIL3 plasmid in mononuclear peripheral blood cells 5, 7, and 10 days after injection of the conjugate. 
Mice were intravenously injected twice with 100µg of anti-CD117-pIL3 conjugate (at day 0 and at day 2). Control group corre-
sponded to mononuclear peripheral blood cells or serum of mice treated with unconjugated pIL3 and anti-CD117 Abs. pIL3 
DNA was only detected in peripheral blood of control animals until day 5 after the first injection. The data are representative 
of three independent experiments.
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The measurement of the weight of the mice and their
organs (liver, kidneys spleen, brain, adrenal glands,
lungs), did not reveal any change, suggesting the lack of
toxicity detected in mice receiving the conjugate (data not
shown). Furthermore, since no IL3 transgene was evi-
denced in these organs, further investigation of potential
toxicity of conjugate might not be relevant.
Finally, clonogenic assay hematopoietic immature cells
were performed on cells removed from sacrificed animals.
As shown in Table 3, their was no differences in mice
receiving the conjugate, control unconjugate, control con-
jugate and mice receiving physiological control serum.
These data clearly demonstrated that our approach did
not alter the hematopoiesis.
Lack of transgene integration
Long-term cultures of bone marrow cells from mice
receiving the conjugate or the controls were performed.
After 1 week of selection in hygromycin-containing
medium (plasmid conferred hygromycin resistance), cells
were cultured for another 2 weeks and then viable cells
were quantified using trypan blue exclusion assay. As
illustrated on Figure 3, upon hygromycin selection, no
viable cell was found in mice transfected with anti-
CD117-pIL3 conjugate, suggesting that there was no inte-
gration of pIL3 into host DNA.
Discussion
Although much progress has been accomplished in the
field of gene therapy over the last years, there is still a need
to develop more effective vectors and new strategies [28].
Using a non-viral gene delivery system, targeting primary
hematopoietic stem/progenitor cells in vitro can be espe-
cially useful for studying the biological effects of various
growth factors [29]. Our conjugate linking an anti-CD117
mAb to a pIL3 plasmid should be a good candidate to tar-
get specifically hematopoietic stem cells. We have
previously reported that the method is suitable for the
production of a functional growth factor in specifically
CD117+ targeted cells, mediating an in vitro biological
effect on hematopoiesis [14]. Since our previous report
evidenced interaction of the conjugate with hematopoi-
etic cells in vitro, the present study focus on specific target-
ing of hematopoietic tissues, in vivo.
We first demonstrated the efficacy of our approach since
the transgene and its product (RNA and circulating
human IL3) were found in mice injected with anti-
CD117/pIL3 conjugate. It is of note that although human
IL3 was only detected in plasma of chloroquine-treated
mice injected with high quantity of conjugate (400µg);
human IL3 encoding RNA were evidenced in treated mice
injected with lower quantity of conjugate (100µg). These
results were in accordance with the design of these exper-
iments aiming at observing even a transitory and local
effect (within the bone marrow).
PCR analyses of tissues evidenced the specific targeting of
the hematopoietic system since brain, liver and lungs were
negative. Only the spleen of mice transfected with the
conjugate and kidneys of control animals (transfected
with unconjugate mixture of Ab and DNA or with the con-
trol conjugate) displayed a positive PCR signal. Observed
shortly after the last plasmid injection in blood, the pres-
ence of plasmid might be due to the intravenous adminis-
tration route used and in kidney, to a progressive
elimination of the plasmid in this organ of refinement.
These results correspond to kinetic of plasmid availability
when not using the specific vector (conjugate) to carry
plasmid into progenitor cells. In the latter case, CD117+
cells were specifically transfected, and among them, Sca1+
cells were positive, suggesting a targeting of hematopietic
progenitor cells via the systemic route.
Several parameters contribute to the efficiency and specif-
icity of our system such as the internalisation of the
antigen targeted, the choice of the transgene used, the tis-
Table 3: Frequencies of colonies in bone marrow following transfection anti-CD117-pIL3 conjugate
Days Control serum Unconjugate Control conjugate Conjugate
mean sd mean sd mean sd mean sd
5 191 10 183 8 192 10 185 25
7 157 55 152 50 192 12 197 16
10 187 23 173 11 182 22 187 26
Number of colonies was measured 5, 7 and 10 days following in vivo transfection with 100µg of anti-CD117-pIL3 conjugate. Control groups 
corresponded to mice injected with unconjugated pIL3 and anti-CD117 mAb or with the control conjugate (G250-pIL3). 5 × 105 cells from bone 
marrow were cultured in complete methylcellulose. Colony (aggregates of more than 40 cells) numbers were evaluated under inverted light 
microscope. The data are representative of three independent experiments and are the mean of triplicate determinations ± S.D.Genetic Vaccines and Therapy 2004, 2:16 http://www.gvt-journal.com/content/2/1/16
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sues targeted, the conformation of the conjugate. Bone
marrow was a good candidate for gene targeting as it is a
highly proliferative tissue, as opposed to tissues which
possess terminally differentiated cells such as hepatocytes
or adipocytes, which are more resistant to transfection
[30].
Factors affecting the bioavailabilty of the administered
conjugates strongly determine their in vivo performance.
These include avid interaction with serum components,
resulting in colloidal instability, including both aggrega-
tion and dissociation of the conjugates and rapid elimina-
tion from blood circulation [31,32]. Therefore, the gene
delivery carrier should function as a protector of DNA dur-
ing in vivo administration. Protamine has been shown to
cause condensation of DNA, which promotes cellular
entry [33,34]. Our complex of plasmid and antibody may
have been sufficiently compacted to resist nuclease degra-
dation and non-specific interaction with plasma proteins.
Furthermore the reduced dimensions of the conjugate
may have been sufficient to allow its diffusibility through
the extracellular space to reach bone marrow cells.
Conclusions
Our gene delivery system is specific and leads to transient
gene delivery and expression. It may prove useful and safe
for numerous clinical applications of gene transfer in
hemato-oncology and radiopathology, whereby a stable
genetic modification is not required, in contrast to the
gene therapy approaches for genetic diseases. For exam-
ple, it may be of interest to facilitate the long-term recon-
stitution of hematopoiesis through transient gene delivery
into progenitor cells of patients after therapeutic and /or
accidental exposure to chemo/radiotherapy. Whether our
approach could be used to potentate hematopoietic
reconstitution following irradiation remains to be
studied.
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Morphology of survival long-term bone marrow cells Figure 3
Morphology of survival long-term bone marrow cells. (a) Long-term bone marrow cells were cultured 7 days. (b) After a 1-
week culture, 50µg/ml of hygromycin was added in order to select for stably transfected cells. After 1 week of selection, these 
cells were cultured 2 weeks in long-term culture medium. Cells observed in controls or in long-term culture in mice injected 
with the conjugate were viable (original magnification ×400).Genetic Vaccines and Therapy 2004, 2:16 http://www.gvt-journal.com/content/2/1/16
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